AAAAAA

   
Results: 1-10 |
Results: 10
GENETIC PREDISPOSITION TO VASCULAR COMPLICATIONS OF DIABETES
Authors: IZMAJLOWICZ ML GROVES C HORTON V OWEN R STRATTON I TURNER RC GREEN FR
Citation: Ml. Izmajlowicz et al., GENETIC PREDISPOSITION TO VASCULAR COMPLICATIONS OF DIABETES, Diabetologia, 41, 1998, pp. 1364-1364
HEPATOCYTE NUCLEAR FACTOR-I-ALPHA (MODY-3) GENE-MUTATIONS IN LATE-ONSET TYPE-2 DIABETES (NIDDM) IN THE UK
Authors: HASHIM Y SOUTHAM L HORTON V MEHTA Z TAGHAVI J SHEPHERD D LATHROP M TURNER R COX R
Citation: Y. Hashim et al., HEPATOCYTE NUCLEAR FACTOR-I-ALPHA (MODY-3) GENE-MUTATIONS IN LATE-ONSET TYPE-2 DIABETES (NIDDM) IN THE UK, Diabetes, 47, 1998, pp. 702-702
UKPDS-21 - LOW-PREVALENCE OF THE MITOCHONDRIAL TRANSFER-RNA GENE (TRNA(LEU(UUR))) MUTATION AT POSITION 3243BP IN UK CAUCASIAN TYPE-2 DIABETIC-PATIENTS
Authors: SAKER PJ HATTERSLEY AT BARROW B HAMMERSLEY MS HORTON V GILLMER MD TURNER RC
Citation: Pj. Saker et al., UKPDS-21 - LOW-PREVALENCE OF THE MITOCHONDRIAL TRANSFER-RNA GENE (TRNA(LEU(UUR))) MUTATION AT POSITION 3243BP IN UK CAUCASIAN TYPE-2 DIABETIC-PATIENTS, Diabetic medicine, 14(1), 1997, pp. 42-45
UKPDS-25 - AUTOANTIBODIES TO ISLET-CELL CYTOPLASM AND GLUTAMIC-ACID DECARBOXYLASE FOR PREDICTION OF INSULIN REQUIREMENT IN TYPE-2 DIABETES
Authors: TURNER R STRATTON I HORTON V MANLEY S ZIMMET P MACKAY IR SHATTOCK M BOTTAZZO GF HOLMAN R
Citation: R. Turner et al., UKPDS-25 - AUTOANTIBODIES TO ISLET-CELL CYTOPLASM AND GLUTAMIC-ACID DECARBOXYLASE FOR PREDICTION OF INSULIN REQUIREMENT IN TYPE-2 DIABETES, Lancet, 350(9087), 1997, pp. 1288-1293
SEQUENCE VARIATIONS IN THE HUMAN KIR6.2 GENE, A SUBUNIT OF THE BETA-CELL ATP-SENSITIVE K-CHANNEL - NO ASSOCIATION WITH NIDDM IN WHITE CAUCASIAN SUBJECTS OR EVIDENCE OF ABNORMAL FUNCTION WHEN EXPRESSED IN-VITRO
Authors: SAKURA H WAT N HORTON V MILLNS H TURNER RC ASHCROFT FM
Citation: H. Sakura et al., SEQUENCE VARIATIONS IN THE HUMAN KIR6.2 GENE, A SUBUNIT OF THE BETA-CELL ATP-SENSITIVE K-CHANNEL - NO ASSOCIATION WITH NIDDM IN WHITE CAUCASIAN SUBJECTS OR EVIDENCE OF ABNORMAL FUNCTION WHEN EXPRESSED IN-VITRO, Diabetologia, 39(10), 1996, pp. 1233-1236
SCREENING FOR MUTATIONS IN THE KIR6.2 SUBUNIT OF THE BETA-CELL K-ATP CHANNEL
Authors: SAKURA H WAT N HORTON V TURNER R ASHCROFT FM
Citation: H. Sakura et al., SCREENING FOR MUTATIONS IN THE KIR6.2 SUBUNIT OF THE BETA-CELL K-ATP CHANNEL, Diabetologia, 39, 1996, pp. 275-275
A PHASE-I CLINICAL-TRIAL OF IMIQUIMOD, AN ORAL INTERFERON INDUCER, ADMINISTERED DAILY
Authors: SAVAGE P HORTON V MOORE J OWENS M WITT P GORE ME
Citation: P. Savage et al., A PHASE-I CLINICAL-TRIAL OF IMIQUIMOD, AN ORAL INTERFERON INDUCER, ADMINISTERED DAILY, British Journal of Cancer, 74(9), 1996, pp. 1482-1486
AUTOIMMUNE DIABETES IN PATIENTS WITH NIDDM - ASSESSMENT BY ICA AND ANTI-GAD AND THE ASSOCIATED PHENOTYPES
Authors: TURNER R STRATTON I ZIMMET P MACKAY I BOTTAZZO F MANLEY S HORTON V
Citation: R. Turner et al., AUTOIMMUNE DIABETES IN PATIENTS WITH NIDDM - ASSESSMENT BY ICA AND ANTI-GAD AND THE ASSOCIATED PHENOTYPES, Diabetologia, 38, 1995, pp. 78-78
AUTOIMMUNE DIABETES ASSESSED BY ICA, ANTI-GAD AND DR3 4 IN POPULATION-BASED COHORT OF PATIENTS WITH NIDDM/
Authors: HORTON V STRATTON I ZIMMET P MACKAY I BOTTAZZO F LO D MANLEY S TURNER R
Citation: V. Horton et al., AUTOIMMUNE DIABETES ASSESSED BY ICA, ANTI-GAD AND DR3 4 IN POPULATION-BASED COHORT OF PATIENTS WITH NIDDM/, Diabetes, 44, 1995, pp. 236-236
PHARMACOKINETICS AND PHARMACODYNAMICS OF IMIQUIMOD (IM)
Authors: HOLTZMAN JL FINLEY DK IMBERSTON L MCCARVILLE S MILLER R KVAM DC HORTON V
Citation: Jl. Holtzman et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF IMIQUIMOD (IM), Clinical pharmacology and therapeutics, 57(2), 1995, pp. 163-163
Risultati: 1-10 |